Galderma Group AG (GALD.SW)
Galderma Group AG operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Zug, ZG, CH. The stock last traded at $176.00, up 0.06% on the session, giving a market capitalisation of $41.04B. Its beta of -0.10 implies it has historically moved less than the broad market.
Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services for the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes Azzalure, ALLUZIENCE, Dysport, Restylane, Restylane Skinboosters, Sculptra, Cetaphil, ALASTIN, Soolantra, Epiduo, Epiduo Forte, Differin, AKLIEF, Oracea, Metvix, NEMLUVIO, Relfydess, Benzac, and Loceryl in therapeutic dermatology. The company was founded in 1981 and is headquartered in Zug, Switzerland.
Galderma Group AG is most often compared with the following Healthcare names: